Dunhill Financial’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.98K Sell
10
-1
-9% -$207 ﹤0.01% 869
2026
Q1
$2.55K Sell
11
-3
-21% -$748 ﹤0.01% 745
2025
Q4
$3.29K Buy
14
+2
+17% +$511 ﹤0.01% 664
2025
Q3
$3.24K Buy
12
+1
+9% +$273 ﹤0.01% 619
2025
Q2
$3.04K Sell
11
-25
-69% -$5.96K ﹤0.01% 621
2025
Q1
$8.04K Sell
36
-2
-5% -$467 ﹤0.01% 462
2024
Q4
$8.72K Buy
38
+7
+23% +$1.69K ﹤0.01% 420
2024
Q3
$7.52K Buy
31
+17
+121% +$3.8K ﹤0.01% 462
2024
Q2
$2.74K Buy
14
+3
+27% +$609 ﹤0.01% 509
2024
Q1
$2.23K Buy
11
+2
+22% +$366 ﹤0.01% 473
2023
Q4
$1.62K Buy
+9
New +$1.38K ﹤0.01% 495

Other funds holding RMD

Dunhill Financial's RMD Position: Q2 2026 in Review

Dunhill Financial reduced its ResMed (RMD) stake by 9.1% in Q2 2026, selling an estimated $207 and leaving 10 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #869.

Dunhill Financial first reported a position in RMD in Q4 2023 and has held it in 11 quarters since. The position peaked at $8.72K in Q4 2024. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Dunhill Financial held 10 shares of ResMed worth $1.98K as of Q2 2026.
  • Dunhill Financial sold 1 ResMed share in Q2 2026, an estimated $207.
  • ResMed made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #869 holding.
  • Dunhill Financial first reported a position in ResMed in Q4 2023 and has held it in 11 quarters since.
  • Dunhill Financial's ResMed position peaked at $8.72K in Q4 2024.
  • 889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.